Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASRT NASDAQ:CRDL NASDAQ:PLUR NASDAQ:SPRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$22.50+0.6%$16.27$8.61▼$22.55$144.18M0.44431,348 shs81,858 shsCRDLCardiol Therapeutics$1.32+1.5%$1.23$0.88▼$1.71$145.36M0.77669,367 shs578,687 shsPLURPluri$3.48+4.2%$3.36$2.82▼$6.10$35.99M0.755,989 shs4,567 shsSPROSpero Therapeutics$2.56+2.0%$2.51$0.57▼$3.22$145.33M1.43482,224 shs355,476 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio0.00%+21.38%+21.51%+75.59%+141.67%CRDLCardiol Therapeutics0.00%-5.80%+0.78%+30.68%+20.93%PLURPluri0.00%-2.21%-1.34%-4.47%-32.62%SPROSpero Therapeutics0.00%0.00%-7.72%+3.72%+334.26%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$22.50+0.6%$16.27$8.61▼$22.55$144.18M0.44431,348 shs81,858 shsCRDLCardiol Therapeutics$1.32+1.5%$1.23$0.88▼$1.71$145.36M0.77669,367 shs578,687 shsPLURPluri$3.48+4.2%$3.36$2.82▼$6.10$35.99M0.755,989 shs4,567 shsSPROSpero Therapeutics$2.56+2.0%$2.51$0.57▼$3.22$145.33M1.43482,224 shs355,476 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio0.00%+21.38%+21.51%+75.59%+141.67%CRDLCardiol Therapeutics0.00%-5.80%+0.78%+30.68%+20.93%PLURPluri0.00%-2.21%-1.34%-4.47%-32.62%SPROSpero Therapeutics0.00%0.00%-7.72%+3.72%+334.26%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASRTAssertio 2.00Hold$19.90-11.56% DownsideCRDLCardiol Therapeutics 2.33Hold$8.50543.94% UpsidePLURPluri 2.00Hold$12.00244.83% UpsideSPROSpero Therapeutics 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest PLUR, CRDL, SPRO, and ASRT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026ASRTAssertio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$18.00 ➝ $21.805/1/2026PLURPluri Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026SPROSpero Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ASRTAssertio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/9/2026ASRTAssertio Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/9/2026ASRTAssertio Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$45.00 ➝ $18.004/9/2026ASRTAssertio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$35.00 ➝ $18.004/6/2026CRDLCardiol Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.003/6/2026ASRTAssertio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold2/10/2026CRDLCardiol Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASRTAssertio$118.71M1.22$0.02 per share1,368.18$14.63 per share1.54CRDLCardiol TherapeuticsN/AN/AN/AN/A$0.11 per shareN/APLURPluri$1.34M27.97N/AN/A($0.11) per share-31.64SPROSpero Therapeutics$66.80M2.22$0.16 per share16.50$1.05 per share2.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASRTAssertio-$30.38M-$4.86N/A20.27N/A-25.59%-30.26%-10.59%5/11/2026 (Estimated)CRDLCardiol Therapeutics-$24.20M-$0.28N/AN/AN/AN/A-239.10%-165.77%5/13/2026 (Estimated)PLURPluri-$22.58M-$4.92N/AN/AN/A-1,890.59%N/A-99.68%N/ASPROSpero Therapeutics$8.57M$0.1221.34N/AN/A12.83%22.53%13.04%5/13/2026 (Estimated)Latest PLUR, CRDL, SPRO, and ASRT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026CRDLCardiol Therapeutics-$0.07N/AN/AN/AN/AN/A5/13/2026Q1 2026SPROSpero Therapeutics-$0.18N/AN/AN/A$43.34 millionN/A5/11/2026Q1 2026ASRTAssertio-$2.1025-$2.93-$0.8275-$2.93$8.97 million$9.93 million3/30/2026Q4 2025CRDLCardiol Therapeutics-$0.09-$0.05+$0.04-$0.05N/AN/A3/26/2026Q4 2025SPROSpero Therapeutics-$0.20$0.53+$0.73$0.53$26.00 million$41.30 million3/16/2026Q4 2025ASRTAssertio-$3.05-$1.86+$1.19-$1.86$6.20 million$13.54 million2/12/2026Q2 2026PLURPluri-$0.65-$0.71-$0.06-$0.71$0.64 million$0.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASRTAssertioN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/APLURPluriN/AN/AN/AN/AN/ASPROSpero TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASRTAssertio0.421.701.51CRDLCardiol TherapeuticsN/A4.164.16PLURPluriN/A0.430.43SPROSpero TherapeuticsN/A7.597.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASRTAssertio48.96%CRDLCardiol Therapeutics12.49%PLURPluri16.59%SPROSpero Therapeutics25.60%Insider OwnershipCompanyInsider OwnershipASRTAssertio5.70%CRDLCardiol Therapeutics5.25%PLURPluri25.93%SPROSpero Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASRTAssertio206.45 million6.08 millionOptionableCRDLCardiol Therapeutics20111.82 million105.95 millionNot OptionablePLURPluri15010.77 million7.98 millionNo DataSPROSpero Therapeutics15057.90 million54.72 millionOptionablePLUR, CRDL, SPRO, and ASRT HeadlinesRecent News About These CompaniesEsther Rajavelu Sells 25,240 Shares of Spero Therapeutics (NASDAQ:SPRO) StockMay 7 at 8:34 AM | insidertrades.comInsider Selling: Spero Therapeutics (NASDAQ:SPRO) Insider Sells 25,240 Shares of StockMay 6 at 11:33 PM | marketbeat.comSpero Therapeutics (SPRO) to Release Quarterly Earnings on WednesdayMay 6 at 7:51 AM | marketbeat.comSpero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026May 5, 2026 | globenewswire.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Sees Significant Growth in Short InterestApril 30, 2026 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Share Price Passes Above 50 Day Moving Average - What's Next?April 16, 2026 | marketbeat.comSpero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business UpdateMarch 26, 2026 | globenewswire.comSpero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026March 18, 2026 | globenewswire.comSpero Therapeutics: Tebipenem's FDA Path Supports A Speculative BuyFebruary 11, 2026 | seekingalpha.comSpero Therapeutics (NASDAQ:SPRO) Insider Sells $207,484.12 in StockFebruary 10, 2026 | insidertrades.comInsider Selling: Spero Therapeutics (NASDAQ:SPRO) Insider Sells 18,442 Shares of StockFebruary 6, 2026 | insidertrades.comWhy Spero Therapeutics, Inc.’s (SPRO) Stock Is Up 7.48%February 4, 2026 | aaii.comAFormer Spero execs fined by SEC over antibiotic efficacy claimsJanuary 20, 2026 | fiercebiotech.comFSpero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including PyelonephritisDecember 19, 2025 | globenewswire.comIs Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans?December 15, 2025 | finance.yahoo.comSpero Therapeutics (SPRO) price target decreased by 20.00% to 4.08December 6, 2025 | msn.comSpero Therapeutics announces inducement grant under Nasdaq listing ruleNovember 29, 2025 | msn.comSpero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 28, 2025 | globenewswire.comSpero Therapeutics Focuses on Tebipenem HBr ProgramNovember 14, 2025 | msn.comSpero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business UpdateNovember 13, 2025 | globenewswire.comSpero Therapeutics (NASDAQ:SPRO) Insider Sells $95,439.90 in StockNovember 13, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 20263 Retail Stocks to Watch for a Post-Tax-Day BumpBy Nathan Reiff | April 13, 2026Investing in Rare Earth Elements: How the REXC ETF Bypasses China’s DominanceBy Jessica Mitacek | April 28, 2026PLUR, CRDL, SPRO, and ASRT Company DescriptionsAssertio NASDAQ:ASRT$22.50 +0.13 (+0.58%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$22.34 -0.16 (-0.71%) As of 05/8/2026 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Cardiol Therapeutics NASDAQ:CRDL$1.32 +0.02 (+1.54%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$1.32 +0.00 (+0.15%) As of 05/8/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Pluri NASDAQ:PLUR$3.48 +0.14 (+4.19%) Closing price 05/8/2026 03:51 PM EasternExtended Trading$3.47 -0.01 (-0.29%) As of 05/8/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.Spero Therapeutics NASDAQ:SPRO$2.56 +0.05 (+1.99%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$2.56 +0.00 (+0.20%) As of 05/8/2026 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
